(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...
Global Respiratory Syncytial Virus Therapeutics Market was valued at approximately USD 5.88 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.82% over the forecast ...
Background: Respiratory syncytial virus (RSV) vaccines could reduce disease burden and costs in older Canadian adults, but vaccination program cost-effectiveness is unknown. We evaluated the ...
RSV infects almost every child before they turn 2, and kills more than 100,000 infants worldwide each year. Machine learning ...
RSV infections affect a significant number of children under age 5, with considerable disease burden in primary care and EDs.
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...
Older adults now have access to two approved vaccines, called Arexvy and Abrysvo. Guidance from the National Advisory Committee on Immunization (NACI) recommends RSV vaccination for any adults aged 75 ...
The arrival of cooler weather and people gathering indoors can lead to the increased spread of COVID-19, influenza and ...
Bronchiolitis alarm in children, there is a life-saving drug but not all Regions can purchase it. The seasonal epidemic of ...
RSV, or respiratory syncytial virus, is a common cause of coughs and colds which can also lead to severe lung infections like ...
Upper respiratory infections (URIs) are some of the most common infections and are caused by a variety of pathogens. Treatment for URIs is usually symptomatic only, if needed, unless a person also has ...
The following is a summary of “Respiratory viral infections from 2015 to 2022 in the HIVE cohort of American households: Incidence, illness characteristics, and seasonality,” published in the August ...